TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1616162
Drug: Meperidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1.5 mg/kg)
Study: 3915058
Drug: Diclofensine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofensine 15 mg
Study: 3915058
Drug: Diclofensine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofensine 25 mg
Study: 25899452
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily
Study: 8722350
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration on day 1 after transplantation (group 1)
Study: 6362846
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of killed C. parvum vaccine
Study: 31201197
Drug: TRAM/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAM/paracetamol
Study: 23020253
Drug: SAXA-MET (saxagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAXA-MET (saxagliptin 5 mg/day added to metformin 1500 mg/day)
Study: 23020253
Drug: MET-UP (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET-UP (metformin uptitration to a maximum dose of 2500 mg/day)
Study: 17905274
Drug: Isoflurane treatment
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane treatment (0.5 MAC)
Study: 17905274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no isoflurane treatment)
Study: 14996603
Drug: L-arginine and
Normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine and vitamin C infusion
Study: 12135314
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C infusion
Study: 2563314
Drug: Esmolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 80 mg I.V. bolus followed by 12 mg/min infusion
Study: 31733088
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.2 mg/kg
Study: 23563904
Drug: Standard-of-care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SoC) treatment
Study: 20088412
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of Granisetron only
Study: 15716033
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with prolonged medical treatment for intractable epilepsy
Study: 9119715
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (ice pack placed on injection site for 15 min prior to injection)
Study: 9119715
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (injections according to hospital protocol)
Study: 31630504
Drug: Perifascial technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifascial technique (20 mL of 10 mg/mL mepivacaine along the latissimus dorsi and superficial axillary fascia)
Study: 31630504
Drug: Perineural technique
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural technique (20 mL of 10 mg/mL mepivacaine around radial, median, ulnar and musculocutaneous nerves)
Study: 9705161
Drug: Capsaicin 0.05%
Normalized name: CAPSAICIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 0.05% applied three times daily for 5 days
Study: 8537137
Drug: Cefixime suspension
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime suspension (8 mg/kg/day, b.i.d., for 10 days)
Study: 8537137
Drug: Amoxicillin-clavulanate suspension
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate suspension (80 mg/kg/day, t.i.d., for 10 days)
Study: 2233283
Drug: Aspartame in
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame in capsules (20 mg/kg)
Study: 28197849
Drug: Myofascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial therapy in addition to a standard physical therapy program
Study: 28197849
Drug: Placebo intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention in addition to a standard physical therapy program
Study: 28197849
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program (both groups)
Study: 27124003
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate tablets from 2 different Chinese pharmaceutical manufacturers
Study: 1489941
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate tablets
Study: 17418968
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of melatonin in the morning (8-9 AM)
Study: 17418968
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of melatonin in the evening (8-9 PM)
Study: 16599071
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with adjuvant therapy (glycoprotein IIB/IIIA receptor inhibitors and clopidogrel)
Study: 1606457
Drug: Fibrinolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agents
Study: 1978373
Drug: Benztropine (BZ)
DrugBank: Benzatropine (DB00245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benztropine (BZ) at 2 mg i.m. and then 1 mg p.o. b.i.d. for 2 days
Study: 25922463
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) therapy for six hours per day (n = 74)
Study: 25922463
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in a plaster cast without IPC (n = 74)
Study: 25922463
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) therapy
Study: 23528027
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (GPIs) during TRA PCI
Study: 21663617
Drug: Wet-cupping treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-cupping treatment
Study: 15671702
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of Hormone Replacement Therapy (HRT)
Study: 9199952
Drug: Enoximone echocardiography
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone echocardiography (1 mg/kg over 5 min)
Study: 8179735
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg syrup)
Study: 26256964
Drug: Triflusal (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (300 mg, b.i.d.)
Study: 26256964
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg, b.i.d.)
Study: 15033211
Drug: Group cognitive-behavior
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavior therapy (Group)
Study: 8421475
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg per day)
Study: 3321483
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg intravenously before operation
Study: 31702047
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g glucose
Study: 12450897
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose
Study: 26902618
Drug: Pre-clipping injection
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-clipping injection group (PG)
Study: 26902618
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection group (CG)
Study: 30664496
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Control)
Study: 23604336
Drug: Methylphenidate (40
Normalized name: methylphenidate (40/60 release) 15 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (40 mg)
Study: 24094274
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments (specific types not detailed)
Study: 19682661
Drug: Rivastigmine 3-12
Normalized name: rivastigmine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 3-12 mg/d capsules
Study: 17430256
Drug: 0.1% captopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% captopril gel
Study: 17430256
Drug: 0.5% captopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% captopril gel
Study: 11160953
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg/d
Study: 11160953
Drug: Lamotrigine 25
Normalized name: lamotrigine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 25 mg/d
Study: 8310507
Drug: 33B3.1 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33B3.1 monoclonal antibody (10 mg/day)
Study: 8310507
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (ATG) (1.5 mg/kg/day)
Study: 8310507
Drug: 33B3.1 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33B3.1 monoclonal antibody
Study: 29747597
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (six-weekly sessions of smoking cessation behavioural-support)
Study: 19032914
Drug: Early use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Study: 18249214
Drug: Initial fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial fasting plasma glucose (FPG) values <100 mg/dL
Study: 18249214
Drug: Initial fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial fasting plasma glucose (FPG) values 100 to 109 mg/dL
Study: 18249214
Drug: Initial fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial fasting plasma glucose (FPG) values 110 to 125 mg/dL
Study: 18249214
Drug: New definition
Approvals — FDA: no, EMA: no, PMDA: no
Description: New definition of IFG including persons with FPG 100 to 109 mg/dL
Study: 18249214
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose levels from 64 to 125 mg/dL
Study: 11420590
Drug: Intramuscular betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular betamethasone 12 mg
Study: 11420590
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 50 mg daily for seven days
Study: 9349933
Drug: Intravenous 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 6-mercaptopurine (1 g.m-2: bolus dose of 0.2 g.m-2 followed by an 8-h infusion of 0.8 g.m-2)
Study: 16204287
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa (0.2 mg/kg) infused intravenously every other week for 4-4.5 years
Study: 12555510
Drug: Naftidrofuryl 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl 200 mg tid
Study: 8099978
Drug: Timing principle
Normalized name: Muguettine principle
DrugBank: Hydroxycitronellal (DB14187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing principle group (vecuronium 0.15 mg.kg‐1 followed by thiopental 5 mg.kg‐1, intubation 60 seconds after thiopental)
Study: 18671864
Drug: Bright blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright blue light therapy (BLT)
Study: 27461
Drug: Vaccine administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine administered by aerosol route, three times a week for 5 weeks (Group I)
Study: 27943546
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg once-daily or twice-daily)
Study: 24015698
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bioactive food ingredients (capsaicinoids, epigallocatechin gallate, piperin, and l-carnitine)
Study: 17094387
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (somatostatin analog octreotide 20 mg i.m. every 28 days + oral dexamethasone 4 mg daily for 1 month, reduced to 1 mg daily by the fourth month, with a 1 mg daily maintenance dose thereafter + zoledronate 4 mg i.v. every 4 weeks)
Study: 9703407
Drug: Tepoxalin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 50 mg twice daily for 3.5 days
Study: 9703407
Drug: Tepoxalin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 200 mg twice daily for 3.5 days
Study: 2685180
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy multicenter trial
Study: 30732996
Drug: Low-dose ferrous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ferrous sulfate (1-3 mg/kg/day)
Study: 23793486
Drug: Self-administered (mailed)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered (mailed) questionnaires
Study: 17673038
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and metformin (500 mg three times daily)
Study: 17673038
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and rosiglitazone (4 mg once daily)
Study: 18226045
Drug: Raloxifene treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene treatment
Study: 12001016
Drug: Oral load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral load of 300 ml of magnesium-rich mineral water (1.2 mmol Mg)
Study: 12001016
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of (28)Mg
Study: 10048795
Drug: High-Fat (HF)
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Fat (HF) treatment
Study: 10048795
Drug: High-Carbohydrate (HC)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Carbohydrate (HC) treatment
Study: 10048795
Drug: High-Protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Protein (HP) treatment
Study: 10048795
Drug: Equal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal mixture (M) treatment (33% protein)
Study: 1919343
Drug: Admission to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission to hospital and treatment with intravenous antibiotics
Study: 29140444
Drug: 1-2 doses
Normalized name: riboflavin 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 doses of 15 μg GI.1/50 μg GII.4c formulation
Study: 26562363
Drug: Dexmedetomidine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (low dose: target plasma concentration of 0.2 ng/ml)
Study: 2014928
Drug: Aqueous BSA
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous BSA solution (10 mg/mL) in a titrated double‐blind, placebo‐controlled bronchial inhalation challenge.
Study: 2014928
Drug: Albuterol metered
Normalized name: albuterol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol metered dose inhaler and avoidance of laboratory exposure to BSA.
Study: 6750813
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g oral glucose load
Study: 27678151
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (12g daily for 12 weeks)
Study: 26448183
Drug: Positive verbal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive verbal suggestion (inert capsule said to be effective for reducing physical sensitivity)
Study: 23839537
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (ADV)
Study: 23839537
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (IDV)
Study: 23839537
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (TIV)
Study: 21223356
Drug: SB-742457 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-742457 (50 mg) + Risperidone (2 mg)
Study: 21223356
Drug: SB-742457 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-742457 (50 mg)
Study: 14719048
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 mg)
Study: 15507864
Drug: Medium-dose balsalazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose balsalazide alone
Study: 12622761
Drug: Controlled-release (Entocort)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (Entocort) capsules
Study: 8588056
Drug: lorazepam 3
Normalized name: lorazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 3 or 4 mg tid
Study: 1778878
Drug: Once-daily amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily amikacin dosing (od)
Study: 1778878
Drug: Twice-daily amikacin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily amikacin dosing (bd)
Study: 30664639
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluoxetine
Study: 24035633
Drug: Lurasidone 80
Normalized name: lurasidone 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 80 mg/day
Study: 23421963
Drug: Lurasidone 120
Normalized name: lurasidone 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 120 mg/day
Study: 24073841
Drug: Lurasidone (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (80-160 mg/day)
Study: 17705186
Drug: Lamivudine therapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine therapy
Study: 12627352
Drug: Lamivudine therapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine therapy for up to 4 years
Study: 16623000
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 100 mg
Study: 6435772
Drug: Alfentanil (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (new analgesic supplement)
Study: 29236238
Drug: 5-week online
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-week online guided self-help intervention based on problem-solving therapy
Study: 26896473
Drug: Tetrahydrobiopterin (BH4)
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tetrahydrobiopterin (BH4) 400 mg single dose
Study: 26896473
Drug: Tetrahydrobiopterin (BH4)
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tetrahydrobiopterin (BH4) 400 mg once daily for 1 week
Study: 24876957
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg and Dexamethasone 8 mg
Study: 12944340
Drug: Moclobemide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (400 mg/day)
Study: 2140382
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg/day)
Study: 21718165
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg twice a day (b.i.d) starting 24 h prior to ascent
Study: 2661989
Drug: Ambroxol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (30 mg, 2 sachets daily for 10 days)
Study: 2661989
Drug: Acetylcysteine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (200-300 mg, 2-3 sachets daily for 10 days)
Study: 15711607
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg o.d.
Study: 15711607
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 100 mg t.i.d.
Study: 12478216
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg/70 kg)
Study: 12680736
Drug: d-Amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (20 mg/70 kg)
Study: 12680736
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg/70 kg) and d-Amphetamine (20 mg/70 kg) conjointly
Study: 8628802
Drug: Textured implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured implants
Study: 24180235
Drug: Ma Zi
Normalized name: ZINC OXIDE 20 g in 100 g TOPICAL OINTMENT [Ancalima Zinc Oxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ma Zi Ren Wan and western medicine placebo
Study: 24180235
Drug: Senna and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna and Chinese medicine placebo
Study: 24180235
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine placebo and western medicine placebo
Study: 21518647
Drug: Control nostrils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control nostrils (no honey treatment)